Antitumor Biologics--Strategies for Success in an Expanding Market

Table of Contents

• Executive Summary
• Strategic Considerations
• Stakeholder Implications
• Introduction
• Existing Biologic Antitumor Agents
• Monoclonal Antibodies
• Rituxan
• Herceptin
• Avastin
• Recombinant Cytokines
• Targeted Cytotoxins and Radiological Agents
• Emerging Antitumor Biologics
• Panitumumab
• Pertuzumab
• Galiximab
• Volociximab
• Mapatumumab
• CAT-3888
• CDP-791
• Herceptin: A Model for Expanding an Agent' s Reach
• Reimbursement Concerns with Anticancer Biologics
• Outlook

Tables

• 1. Select Antitumor Biologic Therapeutic Approaches
• 2. Current Antitumor Protein Drugs, 2006
• 3. Select Emerging Antitumor Biologic Agents, 2006
• 4. Early Stage Approaches to Biological Cancer Treatment
• 5. Critical Clinical Trial Results for Herceptin

Figures

• 1. Antibody Structure
• 2. Number of Anticancer Biologics on the Market, 1995-2006